WO2001024781A3 - Gene necessary for striatal function, uses thereof, and compounds for modulating same - Google Patents

Gene necessary for striatal function, uses thereof, and compounds for modulating same Download PDF

Info

Publication number
WO2001024781A3
WO2001024781A3 PCT/CA2000/001188 CA0001188W WO0124781A3 WO 2001024781 A3 WO2001024781 A3 WO 2001024781A3 CA 0001188 W CA0001188 W CA 0001188W WO 0124781 A3 WO0124781 A3 WO 0124781A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
cag repeat
gene necessary
striatal function
modulating same
Prior art date
Application number
PCT/CA2000/001188
Other languages
French (fr)
Other versions
WO2001024781A2 (en
Inventor
Harold A Robertson
Eileen M Denovan-Wright
Original Assignee
Novaneuron Inc
Harold A Robertson
Denovan Wright Eileen M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2285690 external-priority patent/CA2285690A1/en
Application filed by Novaneuron Inc, Harold A Robertson, Denovan Wright Eileen M filed Critical Novaneuron Inc
Priority to EP00967473A priority Critical patent/EP1223937A2/en
Priority to JP2001527780A priority patent/JP2003510349A/en
Priority to AU77663/00A priority patent/AU7766300A/en
Publication of WO2001024781A2 publication Critical patent/WO2001024781A2/en
Publication of WO2001024781A3 publication Critical patent/WO2001024781A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

PDE10A, a gene that is normally highly expressed in mammalian striatum and elsewhere, has been found to decrease in expression during the development of CAG repeat disorders such as Huntington's disease. The invention teaches a method for detecting the presence of or the predisposition for a CAG repeat disorder. Compounds which modulate CAG repeat disorders and their uses are taught. Methods for screening for further compounds to modulate CAG repeat disorders are also taught.
PCT/CA2000/001188 1999-10-07 2000-10-06 Gene necessary for striatal function, uses thereof, and compounds for modulating same WO2001024781A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00967473A EP1223937A2 (en) 1999-10-07 2000-10-06 Gene necessary for striatal function, uses thereof, and compounds for modulating same
JP2001527780A JP2003510349A (en) 1999-10-07 2000-10-06 Genes required for striatal function, their use, and compounds for regulating them
AU77663/00A AU7766300A (en) 1999-10-07 2000-10-06 Gene necessary for striatal function, uses thereof, and compounds for modulatingsame

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15804399P 1999-10-07 1999-10-07
CA 2285690 CA2285690A1 (en) 1999-10-07 1999-10-07 Gene necessary for striatal function and uses thereof
CA2,285,690 1999-10-07
US60/158,043 1999-10-07
US21776500P 2000-07-12 2000-07-12
US60/217,765 2000-07-12

Publications (2)

Publication Number Publication Date
WO2001024781A2 WO2001024781A2 (en) 2001-04-12
WO2001024781A3 true WO2001024781A3 (en) 2002-02-07

Family

ID=27171056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001188 WO2001024781A2 (en) 1999-10-07 2000-10-06 Gene necessary for striatal function, uses thereof, and compounds for modulating same

Country Status (4)

Country Link
EP (1) EP1223937A2 (en)
JP (1) JP2003510349A (en)
AU (1) AU7766300A (en)
WO (1) WO2001024781A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666886A3 (en) * 2001-04-20 2006-06-21 Pfizer Products Inc. Method of identifying selective PDE10 inhibitor compounds
IL149106A0 (en) * 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
DE10130167A1 (en) * 2001-06-22 2003-01-02 Bayer Ag imidazotriazines
DE10130151A1 (en) * 2001-06-22 2003-01-02 Bayer Ag New use for PDE 10A inhibitors
US20060110783A1 (en) * 2002-11-08 2006-05-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a)
GB0228079D0 (en) * 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
EP1570847B1 (en) * 2002-12-03 2012-04-25 Kyorin Pharmaceutical Co., Ltd. Phosphodiesterase 10a inhibitors for use in the treatment of parkinson's disease, huntington's disease and schizophrenia
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
EP1608743A2 (en) * 2003-04-03 2005-12-28 Memory Pharmaceutical Corporation Phosphodiesterase 10a7 isoforms and methods of use
US20050202550A1 (en) * 2004-03-12 2005-09-15 Pfizer Inc Crystal structure of 3', 5'-cyclic nucleotide phosphodiesterase (PDE10A) and uses thereof
EP2060572A4 (en) 2006-09-06 2010-11-17 Kyorin Seiyaku Kk Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
TW201018682A (en) 2008-09-25 2010-05-16 Kyorin Seiyaku Kk Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient
WO2010041711A1 (en) 2008-10-09 2010-04-15 杏林製薬株式会社 Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US20160222021A1 (en) * 2013-09-11 2016-08-04 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292312A (en) * 1979-06-15 1981-09-29 Henri Griffon Method for preparing alloxan stable aqueous solutions and solutions resulting therefrom
US4367217A (en) * 1980-01-12 1983-01-04 Boehringer Ingelheim Gmbh Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
US5461068A (en) * 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
WO1997003985A1 (en) * 1995-07-14 1997-02-06 Icos Corporation Cyclic gmp-specific phosphodiesterase inhibitors
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5849290A (en) * 1993-02-26 1998-12-15 The General Hospital Corporation Compounds and methods for the diagnosis, treatment and prevention of diseases of cell death
WO1999006545A2 (en) * 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
EP0930069A2 (en) * 1998-01-13 1999-07-21 Johnson & Johnson Medical Ltd. Compositions for the reduction of scarring
US5932423A (en) * 1996-03-25 1999-08-03 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterases
WO1999042596A2 (en) * 1998-02-23 1999-08-26 Icos Corporation Phosphodiesterase 10
WO1999048522A1 (en) * 1998-03-20 1999-09-30 Senju Pharmaceutical Co., Ltd. Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment
WO2000027422A2 (en) * 1998-11-06 2000-05-18 Biogen, Inc. Methods and compositions for treating or preventing peripheral neuropathies

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292312A (en) * 1979-06-15 1981-09-29 Henri Griffon Method for preparing alloxan stable aqueous solutions and solutions resulting therefrom
US4367217A (en) * 1980-01-12 1983-01-04 Boehringer Ingelheim Gmbh Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5849290A (en) * 1993-02-26 1998-12-15 The General Hospital Corporation Compounds and methods for the diagnosis, treatment and prevention of diseases of cell death
US5461068A (en) * 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
WO1997003985A1 (en) * 1995-07-14 1997-02-06 Icos Corporation Cyclic gmp-specific phosphodiesterase inhibitors
US5932423A (en) * 1996-03-25 1999-08-03 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterases
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
WO1999006545A2 (en) * 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
EP0930069A2 (en) * 1998-01-13 1999-07-21 Johnson & Johnson Medical Ltd. Compositions for the reduction of scarring
WO1999042596A2 (en) * 1998-02-23 1999-08-26 Icos Corporation Phosphodiesterase 10
WO1999048522A1 (en) * 1998-03-20 1999-09-30 Senju Pharmaceutical Co., Ltd. Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment
WO2000027422A2 (en) * 1998-11-06 2000-05-18 Biogen, Inc. Methods and compositions for treating or preventing peripheral neuropathies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CEPEDA CARLOS ET AL: "Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons.", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 10, no. 11, November 1998 (1998-11-01), pages 3491 - 3497, XP000998317, ISSN: 0953-816X *
CHEN MINGHUA ET AL: "Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.", NATURE MEDICINE, vol. 6, no. 7, July 2000 (2000-07-01), pages 797 - 801, XP000998293, ISSN: 1078-8956 *
FUJISHIGE K ET AL: "CLONING AND CHARACTERIZATION OF A NOVEL HUMAN PHOSPHODIESTERASE THAT HYDROLYZES BOTH CAMP AND CGMP (PDE10A)", JOURNAL OF BIOLOGICAL CHEMISTRY,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD,US, vol. 274, no. 26, 25 June 1999 (1999-06-25), pages 18438 - 18445, XP000983162, ISSN: 0021-9258 *
ICHIMURA MICHIO ET AL: "KS-505a, an isoform-selective inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase.", BIOCHEMICAL JOURNAL, vol. 316, no. 1, 1996, pages 311 - 316, XP000998314, ISSN: 0264-6021 *
LOUGHNEY K., SNYDER P.B. ET AL.: "Isolation and characterisation of PDE10A, a novel human 3',5'-cyclic nucleotide phosphodiesterase.", GENE, vol. 234, 1999, pages 109 - 117, XP002166002 *
VEMULAPALLI SUBBARAO ET AL: "Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 28, no. 6, 1996, pages 862 - 869, XP000998260, ISSN: 0160-2446 *

Also Published As

Publication number Publication date
EP1223937A2 (en) 2002-07-24
WO2001024781A2 (en) 2001-04-12
JP2003510349A (en) 2003-03-18
AU7766300A (en) 2001-05-10

Similar Documents

Publication Publication Date Title
WO2001024781A3 (en) Gene necessary for striatal function, uses thereof, and compounds for modulating same
ATE271037T1 (en) SUBSTITUTED CARBAZOLES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SPLA2 INHIBITORS
BG102016A (en) Method for the diagnostics of schizophrenia
ZA959037B (en) Method for improving the heap biooxidation rate of refractory sulfide ore particles that are biooxidated using recycled bioleachate solution
AU7264196A (en) Method of screening for factors that modulate gene expression
AU2002246702A1 (en) Method of screening for gpr40 ligands
EP0892048A3 (en) XAF genes and polypeptides and their use for modulating apoptosis
DK0760010T3 (en) Methods for screening for Crohn's disease using TNF microsatellite alleles
EP0911856A3 (en) Getter system for plasma flat panels used as screens
AU7239398A (en) Photostimulable fluorescent pigment and process for producing the same
DK0747526T3 (en) Colored particulate or granular materials from recycled paper as well as process for making the materials
DE69402201T2 (en) PHOSPHORUS-CONTAINING METALLURGICAL SILICON FOR THE PRODUCTION OF ORGANOHALOSILANES
AU2003211040A1 (en) The eaat2 promoter and uses thereof
CA2262769A1 (en) Low viscosity, high solids content slurry
NO995438D0 (en) Methods for screening compounds useful for preventing infection or pathogenicity
WO2000073493A3 (en) A nematode drug screen for modulators of mammalian disorders
AU6091199A (en) Method for determining susceptibility to heart disease by screening polymorphisms in the vitamin d receptor gene
AU4644400A (en) Inkjet ink and ink compositions containing high surface area carbon products
WO2001077380A3 (en) Method for predicting predisposition to a disease associated with mutations in a rpgr gene
AU6091099A (en) Method for determining susceptibility to bone damage by screening polymorphisms in the vitamin d receptor gene
AU6434900A (en) Method for the production of 4,6-dichloropyrimidine with the aid of phosgene
AU6455198A (en) Method for the identification of genetic subtypes
DE69519564D1 (en) METHOD FOR THE PRODUCTION OF 4,4-DIALKYL-6-HALOGEN CHROMANES OR THIOCHROMANS, WHICH ARE USEABLE AS INTERMEDIATE PHARMACEUTICAL PRODUCTS
ATE374229T1 (en) GRANULAR ORGANOSILANE PREPARATION, METHOD FOR THE PRODUCTION AND USE THEREOF
WO2003070179A3 (en) Phosphonate-phosphate and diphosphonate apolipoprotein e modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 527780

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000967473

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000967473

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000967473

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)